title: A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
abstract: OBJECTIVE
  Eribulin mesylate (E7389), a non-taxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analogue of halichondrin B that acts via a mechanism distinct from conventional tubulin-targeted agents. This phase I study determined the maximum tolerated dose (MTD) and pharmacokinetics of eribulin administered on a 3 of 4 week schedule in patients with advanced solid malignancies.
  
  
  METHODS
  Patients received eribulin mesylate (1-hour i.v. infusion) on days 1, 8, and 15 of a 28-day cycle. Dosing began at 0.25 mg/m(2) with escalation guided by dose-limiting toxicities (DLT). MTD, DLTs, safety, pharmacokinetics, and antitumor activity were characterized.
  
  
  RESULTS
  Thirty-two patients received eribulin mesylate (0.25, 0.5, 0.7, 1.0, or 1.4 mg/m(2)). Neutropenia was the principal DLT: At 1.4 mg/m(2), two patients experienced grade 4 neutropenia, one of whom also developed grade 3 fatigue; three additional patients experienced grade 3 neutropenia and were not treated during cycle 1 on day 15. Therefore, the MTD was 1.0 mg/m(2). Fatigue (53% overall, 13% grade 3, no grade 4), nausea (41%, all grade 1/2), and anorexia (38% overall, 3% grade 3, no grade 4) were the most common eribulin-related adverse events. Eight patients reported grade 1/2 neuropathy (no grade 3/4). Eribulin pharmacokinetics were dose-proportional over the dose range studied. One patient (cervical cancer) achieved an unconfirmed partial response lasting 79 days. Ten patients reported stable disease.
  
  
  CONCLUSIONS
  Eribulin mesylate, given on days 1, 8, and 15 of a 28-day cycle, exhibits manageable tolerability at 1.0 mg/m(2) with further dose escalation limited by neutropenia and fatigue.
authors.affiliation: Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Goel
authors.forename: Alain C
authors.initials: AC
authors.lastname: Mita
authors.forename: Monica
authors.initials: M
authors.lastname: Mita
authors.forename: Eric K
authors.initials: EK
authors.lastname: Rowinsky
authors.forename: Quincy S
authors.initials: QS
authors.lastname: Chu
authors.forename: Nancy
authors.initials: N
authors.lastname: Wong
authors.forename: Christopher
authors.initials: C
authors.lastname: Desjardins
authors.forename: Fang
authors.initials: F
authors.lastname: Fang
authors.forename: Mendel
authors.initials: M
authors.lastname: Jansen
authors.forename: Dale E
authors.initials: DE
authors.lastname: Shuster
authors.forename: Sridhar
authors.initials: S
authors.lastname: Mani
authors.forename: Chris H
authors.initials: CH
authors.lastname: Takimoto
mesh_terms: D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D005663:Furans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D050257:Tubulin Modulators / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000095662:Polyether Polyketides
chemical_list: D005663:Furans; D007659:Ketones; D050257:Tubulin Modulators; C490954:eribulin; D000095662:Polyether Polyketides